1
MEDRx (TSE:4586)
H1 FY2022 Business Highlight &
Financial Results
August 30, 2022
These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were prepared based on the plans of MEDRx at the time of disclosure. Actual results may differ from the statements in these materials.
2
Disclaimer and Precautions
- These materials were prepared for the purpose of providing information to assist in making investment decisions. This is not a solicitation to purchase securities issued by MEDRx Co.,Ltd.
- These materials were checked carefully for accuracy, but the completeness of these materials cannot be guaranteed. MEDRx does not accept any responsibility for any problems or damages that result from the information provided in these materials.
- These materials contain forward-looking statements that include estimates, expectations or risks at the time these materials were created. Actual results may differ from these forecasts due to uncertainties such as overall industry and market trends, interest rates and foreign exchange fluctuations, and other economic factors in Japan and overseas.
- MEDRx is not obligated to update or revise the forward-looking statements in these materials even in the event of new information or future events.
These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were prepared based on the plans of MEDRx at the time of disclosure. Actual results may differ from the statements in these materials.
Three Core Transdermal Drug Delivery Platforms
3
Ionic Liquid | Nano-sizedColloid | Microneedle |
Transdermal System | Transdermal System | (MN) |
These materials are distributed directly by MEDRx Co., Ltd. and are available only through direct distribution. MEDRx retains all copyrights to these materials. These materials may not be
copied or reused in any other way, electronically or mechanically, for any purpose without prior consent. Moreover, these materials were preparedCo, ltdbased. All rightson thereservedplans of MEDRx at the time 3of disclosure. Actual results may differ from the statements in these materials.
4
Pipeline : "Primary Target is US market"
Product name | Drug Formulation | Pre | Ph-Ⅰ | Ph-Ⅱ | Ph-Ⅲ | NDA | Launch | |||
Development Code | Development | Clinical | ||||||||
CPN-101(MRX-4TZT) | Worldwide licensing agreement (except for | |||||||||
East Asia) with Cipla USA Inc. | ||||||||||
Spasticity | Phase 1b has got successful result. | |||||||||
(Tizanidine, transdermal, ILTS®) | Phase 2 to be prepared | |||||||||
MRX-5LBT "Lydolyte" | ||||||||||
Receipt of Complete Response Letter | ||||||||||
Neuropathic Pain | Expected to get approval in 2023 after additional study | |||||||||
(Lidocaine, topical, ILTS®) | ||||||||||
MRX-9FLT | ||||||||||
Fast Track designation | ||||||||||
Moderate-Severe Pain | ||||||||||
Clinical Study on-going | ||||||||||
(Fentanyl, transdermal, ILTS®) | ||||||||||
MRX-1OXT | ||||||||||
Phase 1a has got result | ||||||||||
Moderate-Severe Pain | ||||||||||
(Oxycodone, transdermal, ILTS®) | ||||||||||
MRX-7MLL | ||||||||||
Alzheimer's Disease | IND filing | |||||||||
(Memantine, transdermal, NCTS®) | ||||||||||
MRX-6LDT | ||||||||||
Chronic Pain | ||||||||||
(Diclofenac-lidocaine, ILTS®) | ||||||||||
5
Pipeline : "Primary Target is US market"
Product name | Drug Formulation | Pre | Ph-Ⅰ | Ph-Ⅱ | Ph-Ⅲ | NDA | Launch | |||
Development Code | Development | Clinical | ||||||||
CPN-101(MRX-4TZT) | Worldwide licensing agreement (except for | |||||||||
East Asia) with Cipla USA Inc. | ||||||||||
Spasticity | Phase 1b has got successful result. | |||||||||
(Tizanidine, transdermal, ILTS®) | Phase 2 to be prepared | |||||||||
MRX-5LBT "Lydolyte" | ||||||||||
Receipt of Complete Response Letter | ||||||||||
Neuropathic Pain | Expected to get approval in 2023 after additional study | |||||||||
(Lidocaine, topical, ILTS®) | ||||||||||
MRX-9FLT | ||||||||||
Fast Track designation | ||||||||||
Moderate-Severe Pain | ||||||||||
Clinical Study on-going | ||||||||||
(Fentanyl, transdermal, ILTS®) | ||||||||||
MRX-1OXT | ||||||||||
Phase 1a has got result | ||||||||||
Moderate-Severe Pain | ||||||||||
(Oxycodone, transdermal, ILTS®) | ||||||||||
MRX-7MLL | ||||||||||
Alzheimer's Disease | IND filing | |||||||||
(Memantine, transdermal, NCTS®) | ||||||||||
MRX-6LDT | ||||||||||
Chronic Pain | ||||||||||
(Diclofenac-lidocaine, ILTS®) | ||||||||||
This is an excerpt of the original content. To continue reading it, access the original document here.